Thyrocare Technologies Limited has informed the Exchange about Transcript

Thyrocare reported strong Q4 FY '26 results with standalone revenue of INR210 crores (up 21% YoY) and consolidated revenue of INR224 crores (up 20% YoY). Gross margin improved to 74.7% (up 113 bps YoY) driven by volume growth and vendor negotiations. EBITDA margin stood at 34% with PAT of INR48.7 crores (128% YoY growth). For FY '26, consolidated revenue reached INR829 crores with PAT of INR163 crores (81% growth). The company expanded its franchisee network to over 10,800 franchisees and processed 210 million tests (23% YoY growth). Management guided for mid-to-high teens volume growth in FY '27 and expects specialty segment to reach 15-20% of business mix in 3 years. The company also hinted at entering allied consumables business and confirmed genomics expansion underway.